May 9, 2022 -- Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment.
"Why is keeping the product sterile so expensive? Because you've got very expensive cleanrooms and the most expensive thing is the people working in the cleanrooms. So, you have to close the system, you have to automate. You want to put the process in a box and the people outside," Caplan said. "Less people in sterile cleanrooms, closer to the patient, closed loop production -- all these reduce the cost of the product and make it affordable."
Orgenesis has partnered with hospitals to deploy its automated, closed, and flexible Orgenesis Mobile Production Units and Labs (OMPULs) for the development of CGTs. OMPULs can be rapidly deployed as a standardized industrial cleanroom alternative at or near the point of care.
Watch the video below to learn more.
Copyright © 2022 scienceboard.net